BiotechTube
Novocuff

Novocuff

Irvine, United States· Est.
novocuff.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Novocuff is a clinical-stage medical device company targeting the significant unmet need in preterm birth prevention, specifically for conditions like PPROM and cervical insufficiency. Its core technology is the Novocuff Cervical Control System, a device designed to support and close the cervix to retain amniotic fluid and sustain cervical length, with the goal of extending pregnancy. The company is currently conducting an IDE-approved clinical study (RETAIN) in the U.S. and operates as a pre-revenue, private entity. Its success hinges on clinical validation, regulatory approval, and eventual market adoption of its novel device.

Maternal-Fetal HealthObstetrics

Technology Platform

The Novocuff Cervical Control System (CCS), a medical device designed to mechanically support and close the cervix to retain amniotic fluid in PPROM and sustain cervical length in cervical insufficiency.

Funding History

2
Total raised:$1.8M
Grant$250K
Seed$1.5M

Opportunities

The addressable market is large, with PPROM affecting 2-3% of all U.S.
pregnancies and cervical insufficiency being a major cause of preterm birth.
A successful device could command a premium price by significantly reducing the enormous healthcare costs associated with neonatal intensive care.
The novel mechanical approach could fill a major gap where current treatments like cerclage are limited or contraindicated.

Risk Factors

The company faces high clinical risk as the pivotal RETAIN study must demonstrate both safety and efficacy for FDA approval.
Physician adoption may be slow due to the conservative nature of obstetrics and the need to change standard practice.
Securing adequate insurance reimbursement post-approval is a major commercial hurdle.

Competitive Landscape

Direct competition appears limited, as the Novocuff CCS represents a novel device category. The primary current alternatives are cervical cerclage (a surgical stitch) for cervical insufficiency and expectant management/antibiotics for PPROM. Other investigational approaches, such as amniotic sealants or different cervical occlusion devices, may be in earlier development stages at other institutions or companies.

More companies in Drug Delivery & Formulation →More companies in United States →